959578-03-1

Basic information

• Product Name: 3,4-DICHLOROPICOLINIC ACID
• Synonyms: 3,4-DICHLOROPICOLINIC ACID;3,4-Dichloro-2-pyridinecarboxylic acid
• CAS NO: 959578-03-1
• Molecular Formula: C₆H₃Cl₂NO₂
• Molecular Weight: 192.001
• Mol File: 959578-03-1.mol

Chemical Properties

• Boiling Point: 317℃
• Flash Point: 145℃
• Appearance: /
• Density: 1.612
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.95±0.25(Predicted)
• CAS DataBase Reference: 3,4-DICHLOROPICOLINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DICHLOROPICOLINIC ACID(959578-03-1)
• EPA Substance Registry System: 3,4-DICHLOROPICOLINIC ACID(959578-03-1)

Safety Data

• Hazardous Substances Data: 959578-03-1(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
3,4-Dichloropicolinic acid is used as an intermediate in the synthesis of various chemicals, such as herbicides and pesticides, due to its reactive functional groups and compatibility with a range of chemical reactions.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 3,4-Dichloropicolinic acid serves as a building block for the synthesis of pharmaceutical drugs, leveraging its chemical properties to contribute to the development of new therapeutic agents.
Used in Corrosion Inhibition:
3,4-Dichloropicolinic acid is studied for its potential use as a corrosion inhibitor for steel, indicating its application in protecting metal surfaces from degradation and extending the lifespan of steel structures.
Used in Catalysis:
As a reactant in the preparation of ruthenium complexes, 3,4-Dichloropicolinic acid finds application in catalytic processes, where it plays a crucial role in facilitating chemical reactions with enhanced efficiency and selectivity.

InChI:InChI=1S/C6H3Cl2NO2/c7-3-1-2-9-5(4(3)8)6(10)11/h1-2H,(H,10,11)

Upstream product

• 55934-00-4 3,4-dichloropyridine 
• 124-38-9 carbon dioxide 
• 626-60-8 3-Chloropyridine 
• 1211517-04-2 3,4-dichloropicolinaldehyde 

Downstream Products

• 1025720-99-3 3,4-dichloropyridine-2-carboxamide 
• 1203499-43-7 tert-butyl (3,4-dichloropyridin-2-yl)carbamate 
• 1025720-94-8 BMS-777607 
• 1025721-01-0 4-(4-amino-2-fluorophenoxy)-3-chloropyridine-2-carboxamide 

Relevant articles and documents

PHOSPHONATE CONJUGATES AND USES THEREOF

Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.

Antitumor compound used as AXL inhibitor and application of antitumor compound

The invention discloses a compound shown in a general formula (I) or pharmaceutically acceptable salt of the compound and preparation methods of the compound and the salt, and further discloses pharmaceutical composition containing the compound and an application of the compound and the pharmaceutical composition in preparation of an AXL inhibitory drug. The AXL inhibitory drug is used for treating tumor, nephropathy, immune system disease or circulatory system disease.

Electrophilicity and nucleophilicity of commonly used aldehydes

The present approach for determining the electrophilicity (E) and nucleophilicity (N) of aldehydes includes a kinetic study of KMNO4 oxidation and NaBH4 reduction of aldehydes. A transition state analysis of the KMNO4 promoted aldehyde oxidation reaction has been performed, which shows a very good correlation with experimental results. The validity of the experimental method has been tested using the experimental activation parameters of the two reactions. The utility of the present approach is further demonstrated by the theoretical versus experimental relationship, which provides easy access to E and N values for various aldehydes and offers an at-a-glance assessment of the chemical reactivity of aldehydes in various reactions. the Partner Organisations 2014.

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4- ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the met kinase superfamily

Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)- 1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors. Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aqueous solubility and kinase selectivity. Analogue 10 demonstrated complete tumor stasis in a Met- dependent GTL-16 human gastric carcinoma xenograft model following oral administration. Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclinical safety profiles, 10 has been advanced into phase I clinical trials.

PYRIDINONE COMPOUNDS

The invention is directed to pyridinone compounds useful for modulating Met kinase, having the following structure: and is further directed to pharmaceutical compositions comprising the compound; and methods for treating proliferative diseases, such as ca

Strategies for the selective functionalization of dichloropyridines at various sites

Whereas 2,3-dichloropyridine and 2,5-dichloro-4-(lithiooxy)-pyridine undergo deprotonation exclusively at the 4- and 2-positions, respectively, optional site selectivity can be implemented with 2,5- and 3,4-dichloropyridine (which are attacked, depending on the choice of the reagents, at either the 4- or 6- and either the 2- and 5-positions, respectively). Upon treatment with lithium diisopropylamide, 2,4-dichloro-3-iodopyridine, 3,5-dichloro-4-bromopyridine and 2,6-dichloro-3-iodopyridine afford 5-, 2- and 4-lithiated intermediates, but the latter isomerize instantaneously to species in which lithium and iodine have swapped places, the driving force being the low basicity of C-Li bonds when flanked by two neighboring halogens.